The invention relates to a process for the manufacture of a perchlorate depleted milk based on nanofiltration of dairy raw materials. The invention further relates to methods for the preparation of an infant formula base using said perchlorate depleted milk. The invention also envisages a perchlorate depleted retentate fraction used to produce a perchlorate depleted milk and infant formula, an assortment comprising said formula and a system for the manufacture of an infant formula comprising a nanofiltration module.

The invention relates to a process for the manufacture of a perchlorate depleted milk based on nanofiltration of dairy raw materials. The invention further relates to methods for the preparation of an infant formula base using said perchlorate depleted milk. The invention also envisages a perchlorate depleted retentate fraction used to produce a perchlorate depleted milk and infant formula, an assortment comprising said formula and a system for the manufacture of an infant formula comprising a nanofiltration module.

The present invention provides food products, nutritional programs, and methods for meeting nutritional needs of subjects with dementia and related cognitive disorders. In one embodiment, the invention provides a food product comprising a reversibly sealed container and a soup, wherein the soup is in the container and comprises a total volume of 200-2000 mls, a vegetable or meat component, 300 to 2500 calories, a macronutrient caloric distribution comprising: 20-80% fat, 10-45% protein, and 10-65% carbohydrate, about 2% to about 40% medium chain triglycerides, omega 3 fatty acids in an amount of 100 to 2000 mg and less than 20 solid food particles having a volume greater than about 20 cm.sup.3. Such food products, when administered to affected subjects, can positively impact (i) nutritional status; (ii) quality of life; (iii) disease course; (v) the demand for assistance from a care giver; (vi) subject compliance with a nutritional plan using the food product, and (vii) ease of monitoring compliance by the caregiver for verification.

The present invention provides food products, nutritional programs, and methods for meeting nutritional needs of subjects with dementia and related cognitive disorders. In one embodiment, the invention provides a food product comprising a reversibly sealed container and a soup, wherein the soup is in the container and comprises a total volume of 200-2000 mls, a vegetable or meat component, 300 to 2500 calories, a macronutrient caloric distribution comprising: 20-80% fat, 10-45% protein, and 10-65% carbohydrate, about 2% to about 40% medium chain triglycerides, omega 3 fatty acids in an amount of 100 to 2000 mg and less than 20 solid food particles having a volume greater than about 20 cm.sup.3. Such food products, when administered to affected subjects, can positively impact (i) nutritional status; (ii) quality of life; (iii) disease course; (v) the demand for assistance from a care giver; (vi) subject compliance with a nutritional plan using the food product, and (vii) ease of monitoring compliance by the caregiver for verification.

Choline alfoscerate is a drug used to improve cerebrovascular diseases and brain metabolism. It is a drug with proven safety, which has no effect on the kidney and liver and with no severe side effect reported. When administered to a patient with muscle cramps, it can significantly reduce pain and the occurrence of muscle cramps. Accordingly, it may be used as an active ingredient in a pharmaceutical composition for treating or preventing muscle cramps and a health functional food composition for improving muscle cramps and may also be used for a method for treating muscle cramps by administering choline alfoscerate. In addition, choline alfoscerate may also be used to prepare a medication for treating muscle cramps.

Choline alfoscerate is a drug used to improve cerebrovascular diseases and brain metabolism. It is a drug with proven safety, which has no effect on the kidney and liver and with no severe side effect reported. When administered to a patient with muscle cramps, it can significantly reduce pain and the occurrence of muscle cramps. Accordingly, it may be used as an active ingredient in a pharmaceutical composition for treating or preventing muscle cramps and a health functional food composition for improving muscle cramps and may also be used for a method for treating muscle cramps by administering choline alfoscerate. In addition, choline alfoscerate may also be used to prepare a medication for treating muscle cramps.

The present invention relates generally to the field of liquid food compositions. In particular, the present invention relates to liquid food compositions that can be used as dairy alternatives. Dairy alternatives usually do not comprise dairy proteins. For example, such dairy alternatives may comprise alternative protein sources. The liquid food composition of the present invention contains ea protein. Hence, the present invention relates, for example, to a liquid food composition comprising pea protein isolate, sunflower oil, sugar, gellan gum, tribasic calcium phosphate, inulin, dipotassium phosphate, and water, wherein the liquid food composition does not comprise dairy proteins.

The present invention relates generally to the field of liquid food compositions. In particular, the present invention relates to liquid food compositions that can be used as dairy alternatives. Dairy alternatives usually do not comprise dairy proteins. For example, such dairy alternatives may comprise alternative protein sources. The liquid food composition of the present invention contains ea protein. Hence, the present invention relates, for example, to a liquid food composition comprising pea protein isolate, sunflower oil, sugar, gellan gum, tribasic calcium phosphate, inulin, dipotassium phosphate, and water, wherein the liquid food composition does not comprise dairy proteins.

A synthetic nutritional composition comprising a mineral for use to promote, support or optimise de novo myelination, in particular the de novo myelination trajectory, and/or brain structure, and/or brain connectivity, and/or intellectual potential and/or cognitive potential and/or learning potential and/or cognitive functioning in a subject, in particular a formula fed subject.

A synthetic nutritional composition comprising a mineral for use to promote, support or optimise de novo myelination, in particular the de novo myelination trajectory, and/or brain structure, and/or brain connectivity, and/or intellectual potential and/or cognitive potential and/or learning potential and/or cognitive functioning in a subject, in particular a formula fed subject.